Tag Archives: BRAF

June, 2018

May, 2018

December, 2017

  • 21 December

    FDA Approves Bristol-Myers’ Opdivo as Adjuvant Therapy in Melanoma Patients

    PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.1 The purpose of adjuvant therapy is to reduce the …

October, 2017

September, 2017

July, 2017